- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03706144
Evaluating Feasibility and Effectiveness of Computerized Mathematic Training
Evaluating Feasibility and Effectiveness of Computerized Mathematic Training - A Randomized Controlled Trial
Study Overview
Status
Intervention / Treatment
Detailed Description
Computational fluency and understanding of mathematical concepts are essential for students' math achievement. Attainment of math learning goals in childhood uniquely predicts life-course success and wellbeing.Thus, investing in childhood math proficiency is critically important to prepare students for solving problems and succeeding in life. In schools, math teachers are faced with increasingly complex demands but instruction time is limited. Students who are struggling may need extensive individualized practice to succeed. To that end, novel computerized training methods are used in today's schools to help students obtain crucial abilities. According to the National Association for the Education of Young Children (NAEYC), most schools have adopted digital tools in the classroom, and they are increasingly interested in providing students access to new educational resources. Such specialized programs may have the potential to enhance children's academic growth trajectories, but they are not sufficiently evaluated. Moreover, teachers may not be prepared to select and use adequate digital tools.
There are numerous online learning programs that elicit different levels of motivation in students while adhering to Common Core State Standards. Some of them are expensive for schools whereas others are free, which makes them especially attractive for socioeconomically disadvantaged areas. One of the newer, but highly used programs is Prodigy, an adaptive open-access online math training game that continuously adapts to students' progress. Prodigy is different than most other programs because of its play-based, virtual reality environment that students explore with an avatar while solving math questions. As a result, students may be highly motivated and elect to spend more time on Prodigy than on other learning programs. Prodigy is currently being used by around 26 million students and teachers in the United States and Canada (https://www.prodigygame.com/), 150 school districts in the US have implemented Prodigy as part of their math curriculum, and many districts are expected to change from other programs to Prodigy, but the program has not been evaluated so far.
The investigators' aim is to evaluate the use and effectiveness of the adaptive Prodigy math training program via a randomized controlled trial (RCT) in the Knox County Schools (KCS) district.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37996-3531
- University of Tennessee Knoxville
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Elementary and middle school math teachers
- Students grades 2-8
Exclusion Criteria:
n/a
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Prodigy Intervention Group
Teachers will use the Prodigy Math Training with their students in school for at least 20 minutes per day, 3 days per week, from August to December 2018.
|
https://www.prodigygame.com/
|
|
No Intervention: Control Group
Instruction as usual = TAU
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in mathematic achievement
Time Frame: 8 months
|
Change in mathematic achievement trajectories assessed with standardized Aimsweb Concepts and Applications scales test scores at three defined time points over 8 months: baseline (pre-test) assessment is in September, post-test and follow-up assessments take place in early January and late April 2019.
An increase in scores indicates better outcomes (i.e., positive change) over time.
|
8 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Julia Jaekel, PhD, University of Tennessee Knoxville
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- UTK IRB-18-04338-XM
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Math Teachers (Grades 2-8)
-
Peking University People's HospitalNot yet recruitingBusulfan 0.8 mg/kg/q6h (Days -8 to -7) Fludarabine 30mg/m2/Day (Days -6 to -2) Cyclophosphamide 25 mg/kg/Day and r-ATG 2.5 mg/kg/Day (Days -5 to -2)China
-
Yaounde Central HospitalCompletedBenefits of a Hibiscus Sabdariffa and Stevia Rebaudiana Drink in Patients With Type 2 Diabetes Mellitus Before and After 8 Weeks of add-on TherapyCameroon
-
Biohaven Pharmaceuticals, Inc.Active, not recruitingSpinocerebellar Ataxia Type 3 | Spinocerebellar Ataxias | Spinocerebellar Ataxia Type 1 | Spinocerebellar Ataxia Type 2 | Spinocerebellar Ataxia Type 6 | Spinocerebellar Ataxia Type 10 | Spinocerebellar Ataxia Type 7 | Spinocerebellar Ataxia Type 8United States, China
-
Cadent TherapeuticsWithdrawnSpinocerebellar Ataxia Type 3 | Spinocerebellar Ataxias | Spinocerebellar Ataxia Type 1 | Spinocerebellar Ataxia Type 2 | Spinocerebellar Ataxia Type 6 | Spinocerebellar Ataxia Type 10 | Spinocerebellar Ataxia Type 7 | Spinocerebellar Ataxia Type 8 | Spinocerebellar Ataxia Type 17 | ARCA1 - Autosomal Recessive...United States
-
The Hospital for Sick ChildrenActive, not recruitingGroup 1: Healthy Controls | Group 2: Stable CF | Group 3: CF Participants Anticipated to Receive CFTR-modulator Therapy | Group 4: 4-8 yo CF Participants Starting Triple Combination Modulator TherapyCanada
-
Biohaven Pharmaceuticals, Inc.CompletedSpinocerebellar Ataxias | Spinocerebellar Ataxia Genotype Type 1 | Spinocerebellar Ataxia Genotype Type 2 | Spinocerebellar Ataxia Genotype Type 3 | Spinocerebellar Ataxia Genotype Type 6 | Spinocerebellar Ataxia Genotype Type 7 | Spinocerebellar Ataxia Genotype Type 8 | Spinocerebellar Ataxia Genotype...United States
-
University Of PerugiaUnknownThe Primary Study Objective is to Assess the Efficacy and | Safety of Extended 4-week Heparin Prophylaxis Compared to | Prophylaxis Given for 8±2 Days After Planned Laparoscopic | Surgery for Colorectal Cancer. | The Clinical Benefit Will be Evaluated as the Difference in | the Incidence of... and other conditionsItaly
-
ProgenaBiomeWithdrawnAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.Active, not recruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
Sanford HealthNational Ataxia Foundation; Beyond Batten Disease Foundation; Pitt Hopkins Research... and other collaboratorsRecruitingMitochondrial Diseases | Retinitis Pigmentosa | Myasthenia Gravis | Eosinophilic Gastroenteritis | Moyamoya Disease | Multiple System Atrophy | Leiomyosarcoma | Leukodystrophy | Anal Fistula | Spinocerebellar Ataxia Type 3 | Friedreich Ataxia | Kennedy Disease | Lyme Disease | Hemophagocytic Lymphohistiocytosis | Spinocerebellar... and other conditionsUnited States, Australia
Clinical Trials on Prodigy Math Training
-
Alexandria UniversityRecruitingSubstance AbuseEgypt
-
Abbott Medical DevicesCompletedChronic Pain | Intractable PainSpain, Canada, United States, Finland, Germany, Italy, Switzerland
-
The Hospital for Sick ChildrenChildren's Hospital of Eastern OntarioCompletedAttention Deficit Disorder With Hyperactivity | Learning DisordersCanada
-
Damanhour UniversityRecruitingStress | Coherence SenseEgypt
-
University of Southern DenmarkIMK FondenCompletedPhysical Activity | Academic Acheivement
-
Vanderbilt UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...RecruitingMath Learning DisabilityUnited States
-
The Hospital for Sick ChildrenPediatric Oncology Group of OntarioCompletedChildhood Brain TumorCanada
-
Mansoura UniversityEnrolling by invitationPosttraumatic Stress Disorder (PTSD)Egypt
-
University of FloridaFlorida Department of Health; Ocala Royal Dames for Cancer ResearchRecruitingLymphoma, Non-Hodgkin | Acute Myeloid Leukemia | Myelodysplastic Syndromes | Juvenile Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia | Lymphoma, HodgkinUnited States
-
University College, LondonNot yet recruitingChronic Migraine, Headache | Refractory Migraine